Esophageal mucosal protection--why do we need a special approach?
The epidemiology and natural history of reflux induced peptic esophageal diseases remain incompletely understood. That is why it is easy to explain that the traditional therapeutic efforts were mostly restricted to the use of acid-reducing or neutralizing drogs. The author tries to survey--mainly on theoretical bases--a new approach of the maintenance treatment of peptic esophagitis and consequential columnar metaplasia. The mechanism of the esophageal antireflux barrier is composed by the (a) lower esophageal sphincter tone, (b) upper esophageal sphincter tone, (c) esophageal acid clearance and (d) esophageal epithelial resistance. The data of a 100-patient-group of gastroesophageal reflux disease cases were retrospectively evaluated principally considering the efficacy of antisecretory treatment relating to the accompanying diseases, recurrence of symptoms and prevention the development of Barrett's columnar lined esophagus and Barrett's ulceration. The decrease of exposure by damaging factors is an essential criterion of antisecretory therapy, having several disadvantages. Based only to logically well established arguments the author believes that gastroesophageal reflux disease and consecutive conditions might be an ideal model for studying and introducing esophageal cyto (-mucosal, -tissue) protection, considering that in the esophagus--in contradiction to the stomach--the cell and tissue injury, induced by several pathogenic agents, does not develop rapidly, and when the organ damage develops gradually, interventions may be possible to protect esophageal cell and the mucosa directly.
Simon
L
L
Department of Gastroenterology, Tolna County Teaching Hospital, Szekszárd, Hungary.
D001471:Barrett Esophagus / Q000188:drug therapy / Q000503:physiopathology; D004935:Esophageal Diseases / Q000188:drug therapy / Q000503:physiopathology*; D004942:Esophagitis, Peptic / Q000188:drug therapy / Q000503:physiopathology; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D009092:Mucous Membrane / Q000503:physiopathology